Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

• Status: Completed
• Trial end date: 2015-10-07
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to report adverse events of on-treatment AEs by the treating physicians during a specified 24-month study period in patients with venous thromboembolism at the sentinel site(s) for the National Center of Pharmacovigilance (CNFV) in Mexico.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Apixaban

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients 18 years old with DVT and PE at the sentinel site who received at least 1 dose of apixaban for the treatment and/or prevention of recurrence of DVT and PE during the specified 24-month study period

Exclusion Criteria:

• Subjects who received apixaban as part of a clinical trial

• Subjects who received apixaban for any indication other than local approved

• Contraindications included in the approved Mexican prescribing information